Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.

Leconet W, Larbouret C, Chardès T, Thomas G, Neiveyans M, Busson M, Jarlier M, Radosevic-Robin N, Pugnière M, Bernex F, Penault-Llorca F, Pasquet JM, Pèlegrin A, Robert B.

Oncogene. 2014 Nov 20;33(47):5405-14. doi: 10.1038/onc.2013.487. Epub 2013 Nov 18.

PMID:
24240689
[PubMed - in process]
2.

Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma.

Song X, Wang H, Logsdon CD, Rashid A, Fleming JB, Abbruzzese JL, Gomez HF, Evans DB, Wang H.

Cancer. 2011 Feb 15;117(4):734-43. doi: 10.1002/cncr.25483. Epub 2010 Oct 4.

PMID:
20922806
[PubMed - indexed for MEDLINE]
Free Article
3.

The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target.

Koorstra JB, Karikari CA, Feldmann G, Bisht S, Rojas PL, Offerhaus GJ, Alvarez H, Maitra A.

Cancer Biol Ther. 2009 Apr;8(7):618-26. Epub 2009 Apr 22.

PMID:
19252414
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.

Linger RM, Cohen RA, Cummings CT, Sather S, Migdall-Wilson J, Middleton DH, Lu X, Barón AE, Franklin WA, Merrick DT, Jedlicka P, DeRyckere D, Heasley LE, Graham DK.

Oncogene. 2013 Jul 18;32(29):3420-31. doi: 10.1038/onc.2012.355. Epub 2012 Aug 13.

PMID:
22890323
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

AXL regulates mesothelioma proliferation and invasiveness.

Ou WB, Corson JM, Flynn DL, Lu WP, Wise SC, Bueno R, Sugarbaker DJ, Fletcher JA.

Oncogene. 2011 Apr 7;30(14):1643-52. doi: 10.1038/onc.2010.555. Epub 2010 Dec 6.

PMID:
21132014
[PubMed - indexed for MEDLINE]
6.

Enhanced expression of fibroblast growth factor receptor 2 IIIc promotes human pancreatic cancer cell proliferation.

Ishiwata T, Matsuda Y, Yamamoto T, Uchida E, Korc M, Naito Z.

Am J Pathol. 2012 May;180(5):1928-41. doi: 10.1016/j.ajpath.2012.01.020. Epub 2012 Mar 19.

PMID:
22440254
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival.

Vajkoczy P, Knyazev P, Kunkel A, Capelle HH, Behrndt S, von Tengg-Kobligk H, Kiessling F, Eichelsbacher U, Essig M, Read TA, Erber R, Ullrich A.

Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5799-804. Epub 2006 Apr 3.

PMID:
16585512
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Imaging Axl expression in pancreatic and prostate cancer xenografts.

Nimmagadda S, Pullambhatla M, Lisok A, Hu C, Maitra A, Pomper MG.

Biochem Biophys Res Commun. 2014 Jan 10;443(2):635-40. doi: 10.1016/j.bbrc.2013.12.014. Epub 2013 Dec 11.

PMID:
24333418
[PubMed - indexed for MEDLINE]
9.

Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis.

Li Y, Ye X, Tan C, Hongo JA, Zha J, Liu J, Kallop D, Ludlam MJ, Pei L.

Oncogene. 2009 Oct 1;28(39):3442-55. doi: 10.1038/onc.2009.212. Epub 2009 Jul 27.

PMID:
19633687
[PubMed - indexed for MEDLINE]
10.

Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target.

Camp ER, Yang A, Gray MJ, Fan F, Hamilton SR, Evans DB, Hooper AT, Pereira DS, Hicklin DJ, Ellis LM.

Cancer. 2007 Mar 15;109(6):1030-9.

PMID:
17311308
[PubMed - indexed for MEDLINE]
Free Article
11.

SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells.

Chen YW, Hsiao PJ, Weng CC, Kuo KK, Kuo TL, Wu DC, Hung WC, Cheng KH.

BMC Cancer. 2014 Mar 14;14:181. doi: 10.1186/1471-2407-14-181.

PMID:
24625091
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer.

Mishra A, Wang J, Shiozawa Y, McGee S, Kim J, Jung Y, Joseph J, Berry JE, Havens A, Pienta KJ, Taichman RS.

Mol Cancer Res. 2012 Jun;10(6):703-12. doi: 10.1158/1541-7786.MCR-11-0569. Epub 2012 Apr 19.

PMID:
22516347
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.

Hector A, Montgomery EA, Karikari C, Canto M, Dunbar KB, Wang JS, Feldmann G, Hong SM, Haffner MC, Meeker AK, Holland SJ, Yu J, Heckrodt TJ, Zhang J, Ding P, Goff D, Singh R, Roa JC, Marimuthu A, Riggins GJ, Eshleman JR, Nelkin BD, Pandey A, Maitra A.

Cancer Biol Ther. 2010 Nov 15;10(10):1009-18. doi: 10.4161/cbt.10.10.13248. Epub 2010 Nov 15.

PMID:
20818175
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Gas6-induced tissue factor expression in endothelial cells is mediated through caveolin-1-enriched microdomains.

Laurance S, Aghourian MN, Jiva Lila Z, Lemarié CA, Blostein MD.

J Thromb Haemost. 2014;12(3):395-408. doi: 10.1111/jth.12481.

PMID:
24354620
[PubMed - indexed for MEDLINE]
15.

The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target.

Paccez JD, Vasques GJ, Correa RG, Vasconcellos JF, Duncan K, Gu X, Bhasin M, Libermann TA, Zerbini LF.

Oncogene. 2013 Feb 7;32(6):689-98. doi: 10.1038/onc.2012.89. Epub 2012 Mar 12.

PMID:
22410775
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Neuropilin-2-mediated tumor growth and angiogenesis in pancreatic adenocarcinoma.

Dallas NA, Gray MJ, Xia L, Fan F, van Buren G 2nd, Gaur P, Samuel S, Lim SJ, Arumugam T, Ramachandran V, Wang H, Ellis LM.

Clin Cancer Res. 2008 Dec 15;14(24):8052-60. doi: 10.1158/1078-0432.CCR-08-1520.

PMID:
19088020
[PubMed - indexed for MEDLINE]
Free Article
17.

MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival.

Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, Carano RA, Kasman I, Mai E, Young J, Zha J, Zhang Z, Ross S, Schwall R, Colbern G, Merchant M.

Cancer Res. 2008 Jun 1;68(11):4360-8. doi: 10.1158/0008-5472.CAN-07-5960.

PMID:
18519697
[PubMed - indexed for MEDLINE]
Free Article
18.

Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway.

Sawabu T, Seno H, Kawashima T, Fukuda A, Uenoyama Y, Kawada M, Kanda N, Sekikawa A, Fukui H, Yanagita M, Yoshibayashi H, Satoh S, Sakai Y, Nakano T, Chiba T.

Mol Carcinog. 2007 Feb;46(2):155-64.

PMID:
17186543
[PubMed - indexed for MEDLINE]
19.

Evaluation of Tyro3 expression, Gas6-mediated Akt phosphorylation, and the impact of anti-Tyro3 antibodies in melanoma cell lines.

Demarest SJ, Gardner J, Vendel MC, Ailor E, Szak S, Huang F, Doern A, Tan X, Yang W, Grueneberg DA, Richards EJ, Endege WO, Harlow E, Koopman LA.

Biochemistry. 2013 May 7;52(18):3102-18. doi: 10.1021/bi301588c. Epub 2013 Apr 24.

PMID:
23570341
[PubMed - indexed for MEDLINE]
20.

Knockdown of AXL receptor tyrosine kinase in osteosarcoma cells leads to decreased proliferation and increased apoptosis.

Zhang Y, Tang YJ, Man Y, Pan F, Li ZH, Jia LS.

Int J Immunopathol Pharmacol. 2013 Jan-Mar;26(1):179-88.

PMID:
23527720
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk